Monoclonal Antibodies: A New Era In Alzheimer's Treatment
Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...
FiercePharma18h
Eisai execs flag Leqembi 'expansion phase' on the horizon as Alzheimer's med grows slowly
Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...
Biogen receives Market Perform rating at Bernstein ahead of earnings
Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.
Zacks.com on MSN21h
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?
Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...